Monthly Archives: March 2022

If youve ever scanned a field looking for a lucky four-leaf clover, then perhaps youve wondered why they are so rare. It turns out scientists arent exactly sure about the mysteries of four-leaf clovers, either.

The jury is on out why, said Vincent Pennetti, a second-year doctoral student at the University of GeorgiasCollege of Agricultural and Environmental sciences. Pennettis work in theInstitute of Plant Breeding, Genetics and Genomicsfocuses on genetic engineering inturfgrass, but hes also an amateur clover breeder who has gotten pretty good at spotting them in the wild (see more below).

For clovers to produce four leaves, Pennetti said, it takes a combination of genes and environment, but the precise interplay of those two and other factors is still unsolved.

A decade ago, UGA researcherWayne Parrottand his research teamidentified the genetic markersassociated with the four-leaf trait in white clover (trifolium repens), a prevalent species in yards across the U.S.

Parrott, a Distinguished Research Professor incrop and soil sciences, also found the location of other genes that canadd red coloringto white clovers leaves.

But even with markers that could be associated with the four-leaf clover trait, it isnt exactly easy to make your own luck. The four-leaf trait doesnt always show up when expected, even if the genes are present.

Its been a really tough trait to do, Parrott said. If daylight or temperatures arent right, you wont see it. But at other times, five, six, or as many as eight leaves will show up.

Pennettis longtime fascination with clover started while playing little league in Long Island, New York.

My parents really wanted me to be good at baseball, Pennetti recalled. I wasnt. I am not built for sports.

So coaches sent him to the outfield, where he would be less of a defensive liability.

No one was hitting there, he said. I had nothing to do. I was just standing around looking for four-leaf clovers.

But he wasnt having any luck at that either.

Eventually, as a high schooler waiting for the bus, he finally spotted a pair of four-leaf clovers.

And he wanted more.

Thats around the time he learned about Parrotts research concerning multifoliate clover genetic markers at the University of Georgia. Pennetti reached out for advice from Parrott, who in turn gave him pointers on plant breeding over Skype.

Pennetti has been breeding clover ever since. That passion eventually brought him down to Georgia to pursue his doctorate.

While his research focuses on creating better turfgrasses for the consumer market, he remains committed to white clover. He tends to a variety of ornamental clover plants at a UGA greenhouse that have been bred for decorative shapes and leaf markings; some even grow pink flowers

Finding a four-leaf clover isnt easy, but one UGA doctoral student is on a mission to research, find, and breed this mysterious plant. Pennettis personal line of clover, bred from some of the first plants he discovered nine years ago, grow in his basement under an LED lamp. As a side hustle, he preserves and sells four-leaf clovers on Etsy for people who want them as novelties or wedding gifts.

One guy last year ordered $300 worth of clovers just to give out at a senior living community for St. Patricks Day, he said.

Gene-editing technology has opened the door for all sorts of advances in crop sciencesnot to mention the fight against deadly diseases.

With enough research funding and todays CRISPR technology, Pennetti said, it could be possible to create a four-leaf clover in the lab one day. But Pennetti doesnt want to be the one to make that happen.

It would be kind of fun, but on the other hand, I dont want to ruin the search for everybody else, he said. It is nice that its still kind of a mystery.

There is only one four-leaf clover for every 5,076 three-leaf clovers, according to an estimate from the website Share the Luck. But with some strategy and a lot of patience, it is possible to find your own lucky charm. Over the years, Pennetti has gotten good at spotting them.

Here are a few tips for novice four-leaf clover hunters.

1. Find a break in the pattern

Finding multifoliate clovers is really just a pattern game, said Pennetti. Looking at a patch of clover, youll see the typical three-leaf plants create a triangle shape with the whites of their leaves. Look for that triangle pattern to be interrupted.

Most of the time, its going to be three-leaf clovers stuck right next to each, not a four-leaf clover, he said. But sometimes, its a square. And thats actually a four-leaf clover.

2. Grab a good vantage point

Its best to hunt for four-leaf clovers on your feet. That will give you the distance from the ground you need to spot breaks in the pattern when trying to distinguish from your typical shamrock.

Never go on your hands and knees, Pennetti said. Youre going to waste so much time.

3. Keep moving

Dont linger in any one patch of clover. Instead, keep moving during your search.

Dont spend too much time in one area, Pennetti said. Its either going to be there or it isnt.

Happy hunting. And good luck.

Sponsored Content on AGDaily

Link:
The science and secrets of four-leaf clovers - AGDAILY

[Illustration: ipopba/iStock]

Our capital, Austin, has a reputation for attracting businesses at the cutting edge of the sciences, but it is hardly the only bright spot for innovation in the Lone Star State. In fact, venture capital funding is flowing into Dallas-Fort Worth at a faster rate than any other area in the nation. When it comes to the biotech industry, our region is leading the U.S. in key metrics of job growth and investment.

This success in North Texas is not a coincidence, but the result of strategic collaborative efforts and a shared ambition of key players across this regions biotech ecosystem. The collective efforts of government, nonprofit, academic, and industry partners have brought together the necessary ingredients to enable sustainable long-term growth.

Emblematic of this collaboration is the forthcoming Texas Instruments Biomedical Engineering and Sciences Building, a joint partnership between UT Southwestern Medical Center and The University of Texas at Dallas. By integrating biomedical engineering with advances in related fields such as artificial intelligence, molecular imaging, robotics, and genetic engineering, this collaboration will further solidify North Texas reputation as a hot market for biomedical innovation.

The quality of innovation emanating from our nationally ranked hospital systems and research centers can be credited in a large part for growing investor interest. But good science alone isnt enough. DFW produces, attracts, and retains the skilled workforce our industry partners need to scale up operations. This has paved the way for companies like Taysha Gene Therapies and Caris Life Sciences to make the strategic decision to headquarter and innovate here.

Another indicator of our regions long-term stability is Biolabs selection of Dallas as its ninth location in the U.S. This brand-new 32,000-square-foot flexible lab, training, and office space at Pegasus Park has addressed a previously critically deficient element of our healthcare innovation ecosystem. DFWs historic lack of available commercial laboratory space has been a recognized hindrance to the growth and retention of the early-stage startups that are the lifeblood of this industry. This available lab space is in high demand and is on track to achieve full occupancy in the short term.

Kendall Square (in Cambridge, MA), South San Francisco, and La Jolla (north of San Diego) are all power clusters that have pulled away several of our regions innovators and their startup companies through the undeniable allure of easy flow of venture capital dollars and access to a highly skilled workforce. These same regions are now facing their own challenges, from unaffordable housing to urban congestion, that are causing real reductions in quality-of-life metrics. In that respect, our timing couldnt be better to support critical elements that will enable continued biopharma and healthcare innovation growth.

In fact, we possess another enormous asset that those other innovation hubs do not. Dallas Fort Worth International Airports cold chain logistics capabilities enable the distribution of fragile biologic and pharmaceutical medicines to anywhere in the world in a matter of hours while maintaining essential and highly specific conditions. Only one other airport in the U.S. possesses logistics close to this scale.

DFW further benefits from fantastic state and local government partners in driving sound economic development choices that are supporting our growth as a biotech hub. These capabilities and our famously business friendly environment attracted McKesson, the nations largest pharmaceutical distributor, to relocate to North Texas four years ago.

The rapid rise of Pegasus Park as the center of our regions life sciences hub now equips North Texas with its own hugely scalable version of the clusters found on the coasts. Similarly, plans have been announced for Texas A&M to expand their Fort Worth presence with a research campus that will advance medical innovation and drive business development. In order to maintain this momentum and realize significant industry growth, we must continue to build and improve access to ready capital for investment in all stages of biopharma innovation.

Other national partners like MassChallenge have begun to make an impact by creating the environment needed to promote and attract access to funding and entrepreneurial resources. BioNORTHTEXAS is also developing our own Investor Forum that will soon attract national funding partners as we match them with researchers and startups.

With government, industry, and academia working together, there is not a problem that we cannot solve. This is an exciting time for our industry and region as we drive towards a more innovative and prosperous future.

Views and opinions expressed by Voices contributors are their own.

Kathleen Otto (left) and George Goodno

Kathleen Otto is the CEO at BioNORTHTEXAS. She previously served as executive director of New York Citys Science and Technology Center at the Brooklyn Army Terminal, and as Vice President of Business Development and Programs at Bio New Jersey.

George Goodno is a Senior Advisor for the ENTENTE Network, providing communications and management consulting services to biopharma and healthcare clients. Previously he served as the Director of Industry Relations for UT Southwesterns Office for Technology Development and Director of Communications for the national trade group Biotechnology Innovation Organization. Goodno presently serves on advisory councils for BioNTX and Healthcare Think Tank.

Sign up to keep your eye on whats new and next in Dallas-Fort Worth, every day.

BioLabs at Pegasus Park shared space and state-of-the-art lab is slated to open in December. It's a place where entrepreneurial innovators can test, develop, and grow their ideas.

Rare is not that rare, says the RDCC. One in ten people lives with a rare disease, and the new coalition will unify life science companies dedicated to developing treatments. The goal? To inform policymakers of the unique challenges in the space. Signature Biologics joins Dallas-based Taysha as a member of the RDCC.

The summit is an innovation multiplier for capital, collaboration, and commercialization. Plus, you can meet 2021 NTX Rising Starsand the new companies moving to BioLabs at Pegasus Park. Here's an updated agenda for the annual iC3 Life Science Summit on September 30 and October 1.

Now valued at more than $7.8 billion, Caris specializes in AI-powered genetic sequencing for personalized cancer treatments. The massive capital raise follows a $310 million round in October and boosts the 13-year-old company's total funding to about $1.3 billion.

The agreement will involve the two companies providing educational programs and connections for scientist entrepreneurs located at the Biotech+ Hub at Pegasus Park.

As the former CEO of the Perot Museum of Nature and Science from 2002 to 2014, Nicole Smalls passion for philanthropy and STEM education firmly prepared her for her current role as president of the Lyda Hill Foundation and CEO of LH Holdings Inc.

Biotechnology is alive and growing in DFW. The region recently ranked 6th on a list of top ten emerging life science clusters in the U.S.

Pharma relocations, venture capital, and $6 billion in the State of Texas CPRIT Fund are priming North Texas to be a life sciences mecca, says Transwestern's John Huff.

Alcon gave rise to a startup ecosystem in North Texas that is spreading into all parts of how drugs, medical devices, and more are created.

See the rest here:
Collaboration Is the Key to North Texas' Emergence as a Bio-Hub Dallas Innovates - dallasinnovates.com

Polybion bacterial cellulose membrane, ready for stabilisation and tanning to make Celium ... [+] 'leather-alternative'

The response to this series of next-gen materials articles has been feverish. It seems to have flung open the doors of labs and manufacturing facilities across the globe, sending a deluge of materials innovations and technology platforms my way, which all have a role to play in replacing toxic and resource-hungry incumbent materials. As a result, this series will be extended, but today, we journey to Polybion HQ in Mexico, to unravel natures most elegant and effective integrated recycling and material production unit: bacteria.

In a world where industrial recycling infrastructure is fragmented and ill-equipped to deliver material circularity, a solution in nature has been staring us in the face, literally, forever. Bacteria are Earth's most abundant species and simplest organisms, evolving for 3.5 billion years, surviving mass extinctions and extreme environmental swings along the way. This has made them highly resilient and efficient at conducting biochemical reactions in symbiosis with nature. Such reactions include metabolizing waste back into the building blocks of natureno industrial infrastructure needed.

Bacterias simplicity as single-celled organisms makes them microscopic powerhouses that produce useful substances (including cellulose) during their natural metabolic processes. Guanajuato-based startup Polybion leverages this, adding a layer of bioengineering to re-code bacterias genes to orchestrate specific metabolic outputs, thereby creating new biomaterials. The first of these is a cellulose membrane, which the bacteria bio-assembles into a skin that can be tanned and used as a leather alternative, which they call Celium.

On the subject of leather alternatives, Mycelium, which is grown from fungi, has experienced a surge in interest, winning the favor of brands including Allbirds who are working with NFWs Mirum, and Hermes with Mycoworks Fine Mycelium. So why is Polybion using bacteria instead of fungi, and what is the difference between the material outputs?

During a video interview with the Polybion team, co-founder and CEO Axel Gmez-Ortigoza explained bacteria have simpler genomes and are easier to genetically engineer than fungi. And taking natures lead, he added that cellulose is the most abundant (and perhaps versatile) polymer on the planet; so with bacteria producing it, the potential for scalable, modular, and high-yielding biomaterials is immense. Bacterias high yield is the deal-breaker, he added, offering faster scaling and more predictable, repeatable material outputs than fungi-based alternatives.

Polybion uses local agro-industrial food and water to feed their engineered bacteria in an industrial fermentation unit. The bacteria grows the cellulose membrane on the surface of the water by consuming glucose and fructose from the food waste and polymerizing it into cellulose, which takes 20 days.

Bacterial cellulose fermentation in industrial unit

The membrane is removed and transported to a nearby tannery where it is stabilized (to halt the live decay process) and tanned using a chrome-free method that is REACH and Environmental Protection Agency (EPA) compliant. Importantly, the stabilization and tanning of Celium requires no new infrastructure, just optimized chemistry and water usage within existing tanning facilities. This entire process, from raw material to finished skin happens within a 30-mile radius of Irapuato, in Guanajuato, Mexico.

In December 2021 Polybion launched the first industrial-scale, bacterial cellulose textile, biomanufacturing facility in the world: a 14,500 sq. ft solar-powered, carbon-neutral facility. Production volumes of Celium at this pilot factory are currently 350,000 sq. ft. per year, rising to 1.1 million by Q4 2023.

Production volumes are partially dependent on locally available waste, but of this, there is no shortage (as is true of any location on the planet with both people and industrial agriculture). The fruit waste within a 30-mile radius of FOAK I (Polybions pilot facility) could produce 165 million sq. ft. Celium per year: equivalent to 1% of the global leather market.

During the video interview, Axel and his co-founder, CFO, and brother, Alexis Gomez-Ortigoza, forecast that the technology will scale 10X after pilot capacity is reached in 2023, supported by licensing of the technology to drive rapid (and probably European) expansion.

Finished Celium 'canvases'

Its important to note that the R&D to reach this stage of production took 6 years, and was achieved with, incredibly, only 4 million ($4.4 million). This CapEx is tiny compared to similar next-gen material innovations, so how did they manage so much with so little? The brothers say this is a result of strictly prioritizing the development of the technology and focusing on science-based problem-solving, and avoiding marketing and promotional spending during development stages. Axels excellence in bioengineering, and Alexiss finance background, added to the nearby leather industry knowledge and infrastructure have also helped, no doubt. A key takeaway from this interview, I believe, is the promise of ingenuity and persistence, even in the face of modest financial resources. Its also a fair, and probably overdue, reminder that critical innovation is happening all over the globein every corner, in every region, and every culture.

Celiums sustainability gains are commensurate with adopting biological processes in place of synthetic ones. Microorganisms do not require land clearing, nor do they need daily water replenishment. They are not methane emitters, in contrast to livestock, and avoid PU and PVC which cause microplastic pollution. In fact, Celium is a holistically designed biomaterial, as opposed to the vast array of plant-based and plastic based leather alternatives on the market that are composites of plant fibres and plastic polymers that rendering them marketable as vegan but environmentally suspect.

Polybion provided some headline resource consumption figures to flesh out the impact reduction: cowhide tanning uses approximately 30 liters of water per square foot. By comparison, the stabilization process of Celium uses about 5 liters; Its tanning also avoids heavy metals including chrome.

Regarding up-cycling, 1,200 metric tons of fruit waste will be processed per year at maximum capacity, helping prevent around 3000 metric tons of CO2 from entering the atmosphere. Celium's carbon footprint arises wholly from transportation and logistics and stands at 0.792 kilograms of CO2eq per square foot. I balk at material impact comparisons, but to share the information they provided for context, Polybion places Celium at around half the emissions impact of animal and plastic leathers. Celiums calculated impacts will be revealed in detail upon receipt of the final Life Cycle Assessment (LCA).

Polybion FOAK I pilot facility for Celium production

The startups strategy for collaboration and expansion is to target affordable luxury and premium global brands that produce high volumes. We are working with forward-thinking, global consumer brands across multiple sectors ranging from affordable luxury to premium and high-end shares their Head of Communication and Culture, Gabriela Irastorza Dragonn. Their brand partners span fashion, accessories, shoe, and automotive sectors, and the technology they have developed is suitable for materials spanning food and pharma industries too.

With a series A funding round under their belt, led by Blue Horizon, next on Polybions agenda is genetically engineering bacteria strains to boost Celiums performance, the hand feel, and overall appearance. They are pursuing recombinant materials (from organisms with recombined genetic material) never seen before by mankind, designed and grown using lifes molecular palette. The output? Hybrid Organic Metamaterials. Meta indeed, thanks to 3.5 billion years of natures wisdom combined with advanced technology and human ingenuity: perhaps the best recipe for the next generation of environmentally responsible materials.

Follow this link:
Bacterial Leather From Food Waste: Next-Gen Circular Materials Are Alive (And Ready To Scale) - Forbes

ReportLinker

Plant Breeding & CRISPR Plants Market Research Report by Process (Hybridization, Mutation Breeding, and Selection), by Trait (Disease Resistance, Herbicide Tolerance, and Yield Improvement), by Type, by Application, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

New York, March 17, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Plant Breeding & CRISPR Plants Market Research Report by Process, by Trait, by Type, by Application, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06226244/?utm_source=GNW

The Global Plant Breeding & CRISPR Plants Market size was estimated at USD 8,982.77 million in 2020 and expected to reach USD 10,295.16 million in 2021, at a CAGR 15.04% to reach USD 23,956.53 million by 2027.

Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2027 are considered the forecast period.

Market Segmentation & Coverage:This research report categorizes the Plant Breeding & CRISPR Plants to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Process, the market was studied across Hybridization, Mutation Breeding, and Selection. The Hybridization is further studied across Bulk Method, Double Cross, Pedigree Method, Single Cross, and Three-Way Cross. The Selection is further studied across Mass Selection and Pure Line Selection.

Based on Trait, the market was studied across Disease Resistance, Herbicide Tolerance, and Yield Improvement.

Based on Type, the market was studied across Biotechnological Method and Conventional Breeding. The Biotechnological Method is further studied across Genetic Engineering, Genome Editing, Hybrid Breeding, and Molecular Breeding.

Based on Application, the market was studied across Cereals & Grains, Fruits & Vegetables, and Oilseeds & Pulses.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Plant Breeding & CRISPR Plants Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitors strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Plant Breeding & CRISPR Plants Market, including Advanta Seeds Pty Ltd, AgriSeq Solutions Inc., Bayer AG, Benson Hill Biosystems, Inc., BioConsortia, Inc., Cibus, Ltd., DLF Seeds Ltd, Dow Dupont, Equinom, Eurofins Scientific, Evogene, Groupe Limagrain, Hudson River Biotechnology, J.R. Simplot Company, KWS SAAT SE & Co. KGaA, Land Olakes, Pacific Biosciences of California, Inc., Pairwise, SGS S.A., Syngenta Group, Tropic Biosciences UK LTD, and Yield10 Bioscience, Inc..

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:1. What is the market size and forecast of the Global Plant Breeding & CRISPR Plants Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Plant Breeding & CRISPR Plants Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Plant Breeding & CRISPR Plants Market?4. What is the competitive strategic window for opportunities in the Global Plant Breeding & CRISPR Plants Market?5. What are the technology trends and regulatory frameworks in the Global Plant Breeding & CRISPR Plants Market?6. What is the market share of the leading vendors in the Global Plant Breeding & CRISPR Plants Market?7. What modes and strategic moves are considered suitable for entering the Global Plant Breeding & CRISPR Plants Market?Read the full report: https://www.reportlinker.com/p06226244/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

More here:
Plant Breeding & CRISPR Plants Market Research Report by Process, by Trait, by Type, by Application, by Region - Global Forecast to 2027 -...

When a radio talk-show host insisted last year that you can grow concrete, he was mercilessly ridiculed on social media. While his argument was uninformed, does bioengineering mean it could one day be possible to grow concrete on a small scale?

Concrete is the most widely used man-made material, and second only to water as the most-consumed resource on Earth. Incredibly, 7.3 billion cubic metres of concrete is poured every year, accounting for 8per cent of carbon dioxide emissions.

While greener concrete may help curb some of the environmental damage done by our favourite building material, we will probably need even more of it. After all, our growing global population, which is expected to top 9.7 billion by 2050, will need new homes and we will need efficient ways to maintain current houses and infrastructure too.

Self-healing concrete is one part of the solution to this global challenge. Engineers have developed forms of it that contain capsules which release a healing agent to fix cracks when they are split open. Using this new wonder material could save millions of pounds every year in maintenance costs, not to mention disruption caused by repairs to tunnels, bridges and other concrete infrastructure.

The problem with conventional reinforced concrete is that stress gradually creates small cracks, allowing water and oxygen to penetrate the steel in the concrete, causing it to corrode. This could in turn cause serious damage to the structure.

Hendrik Jonkers, professor of bio-adapted and sustainable building materials at Delft University of Technology in the Netherlands, has discovered a special ingredient that enables concrete to heal itself: bacteria that are usually found in stone. He has been able to create self-healing bio concrete by embeddingbacterial spores, which are like seeds for bacteria, in a concrete mix.

When cracks start to appear in the bio concrete, water and oxygen infiltrate it and activate the spores, causing the bacteria to multiply. This ensures a wide distribution of bacteria inside the crack. The widely dispersed bacteria will start to convert the nutrients in the spores into calcium carbonate, or limestone, which will eventually seal the crack. This essentially heals the concrete using a process found in nature called biomineralisation the same process that often results in plaque forming on your teeth.

What makes these limestone-producing bacteria so special is that they are able to survive in concrete for more than 200 years and come into play when the concrete is damaged, Professor Jonkers explains. Using this new material in construction gives buildings real longevity.

The technology, which was developed and patented in collaboration with the Delft University of Technology, has been commercialised. Basilisk Self-Healing Concrete sells an admixture, suitable for building new structures, along with two more products that can be applied to existing buildings to boost their durability.

Basilisks self-healing products have been used by a Dutch railway firm and in the construction of the Port of Rotterdam, while JP Concretes Sensicrete is the first self-healing concrete available in the UK and the company hopes to see the material being used in new builds and infrastructure in the country soon.

The only prohibitive factor is cost. Self-healing concrete is not the sort of thing that would be, currently at least, considered economically viable for normal construction. It tends to be on mission-critical infrastructure, where the benefits of long-term robustness of the material far outweigh the initial costs, says Martyn Dade-Robertson, professor of emerging technology and co-director of the Hub for Biotechnology in the Built Environment at Newcastle University.

However, he thinks biotechnology will revolutionise the construction industry, and wants to use the capacity of microorganisms to sense and respond to their environment, as well as add to it with their own structures.

The concept behind our project, Thinking Soils, is that you have bacteria in soil that can detect mechanical pressure, Dade-Robertson explains. This could trigger biomineralisation, which is the same process used by self-healing concrete. We could create a self-constructing foundation just by putting the right amount of pressure on the ground, removing the need for costly excavations and reinforced concrete slabs.

Unsurprisingly, making this a reality is difficult. His team has identified genes in certain bacteria that activate in response to pressure. We want to engineer those responses, says Dade-Robertson, who, through synthetic biology, has used genetic engineering to design bacteria that glow under pressure.

The next step is making an enzyme thats responsible for the biomineralisation process. Its a very complicated enzyme to make, but what were trying to do is get an engineered system that will lead to the enzyme being created in response to the genetic switch in bacteria being triggered by a load. The researchers are getting very close to managing this, but putting different processes together will be a challenge. They intend to create a demonstrator where they can load a material and from it produce calcium carbonate crystals, essentially using its pressure-sensing capacity to trigger biomineralisation. Dade-Robertson admits the project is ambitious, but says it is about creating a new class of material.

Growing small-scale deposits to bind particles together and fill cracks is neat. But could we one day grow materials into forms and structures that are building-ready, essentially growing parts of a house? Professor Dade-Robertson says this probably isnt too far off.

A US firm already makes decorative stone using biomineralisation, while a British start-up called Biohm soon plans to manufacture blocks of insulation from mycelium, which is the root network of a fungus.

These biotech feats are impressive, but the next step is to engineer living materials that can be used in construction. For example, biodegradable microbial cellulose materials can be grown to take the place of plastic, like in eco-friendly food packaging. But what if youcould turn the materials ability to biodegrade on and off? According to Dade-Robertson,if that was possible it could one day be used to construct environmentally friendly buildings. For example, once someone had finished living in a cellulose-based dwelling, the biodegradable switch could be turned on and the building would disappear.

The development of materials that retain their life-like properties takes this idea one step further. For example, instead of drying mycelium to produce insulating bricks, the mushroom roots could be kept alive. It could grow thicker in the winter to keep you warm, Dade-Robertson muses.

In fact, Nasa is interested in whether mycelium might be a good material to use for building on Mars. As mycelia normally excrete enzymes, it should be possible to bioengineer them to secrete other materials on demand, such as bioplastics or latex to form a biocomposite, says Lynn Rothschild at Nasa Ames Research Centre. A mycotectural building envelope could significantly reduce the energy required for building because in the presence of food stock and water it would grow itself.

A group at MIT has developed materials made of layers of bacterial spores and latex that can change their shape in response to water. While their focus was on clothing, Dade-Robertsons group is exploring whether this method could be used to make building membranes that could sweat as indoor humidity rises, negating the need for mechanical air-conditioning systems. Using latex membranes coated with bacteria spores the material will flex and open pores like sweat glands allowing air to flow through the walls, he says.

Elsewhere, others are also working on the creation of a living building material. Wil Srubar, professor of architectural engineering and materials science at the University of Colorado Boulder, has used photosynthetic cyanobacteria the green microorganisms that grow on the walls of fish tanks to help grow a building material that can be kept alive.

The cyanobacteria use carbon dioxide and sunlight to grow, and can create bio-cement, which Srubars team used to help bind particles of sand together to form a brick.

By keeping the cyanobacteria alive, we were able to manufacture building materials exponentially. We took one living brick, split it in half and grew two full bricks from the halves, he says. Such a technique could certainly come in handy on a building site and could save energy too.

While the manufacture, transport and assembly of building materials account for 11per cent of global CO2 emissions, living building materials such as cyanobacteria bricks could sequester CO2.

An expandable house could even be on the cards. Imagine youve got a building that starts growing bricks for an extension as your family grows, so your house grows with you, Dade-Robertson says. While he acknowledges this is far-reaching stuff, there is fundamental research going on that could lead us in this direction, making sci-fi-worthy ideas a reality.

If he is right, our eco-friendly homes will be a far cry from the futuristic glassy skyscrapers of Minority Report, or swanky apartments in Blade Runner, instead taking their inspiration from nature. Self-healing concrete and mushroom bricks are amazing, but we have only scratched the surface of the potential of bioengineered building materials. Organisms could bring living functions to building blocks, such as responding to temperature or pressure, self-healing or even lighting up. As Professor Srubar says: If nature can do it, living materials can be engineered to do it, too.

Innovation

Sign up to the E&T News e-mail to get great stories like this delivered to your inbox every day.

Visit link:
How to grow concrete and other building materials - E&T Magazine

IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence after IND submission

Entered into a strategic collaboration with Bristol Myers Squibbto develop iPSC-derived allogeneic cell therapies

Ended 2021 with cash, cash equivalents, and marketable securities of $358.8M; Cash runway into 2025, including proceeds received from Bristol Myers Squibb in connection with the Collaboration Agreement

PHILADELPHIA, March 17, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc., (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2021.

Throughout 2021, we continued to make steady progress in developing our comprehensive, next-generation iPSC-based cell therapy platform, executed on our powerful discovery engine, and we believe we are positioned to transition to a clinical stage company in 2022. With this foundation in place, we are on track to advance multiple product candidates to the clinic over the next three years, said Lalo Flores, Chief Executive Officer, Century Therapeutics. Additionally, we look forward to continuing our partnership in the years ahead with Bristol Myers Squibb, a global leader in oncology and hematology, to further expand our pipeline of iPSC-derived cell therapy products for treating hematological and solid tumor malignancies. We are committed to maximizing the potential utility of our platform technology and look forward to what we expect to be a very productive year ahead.

Business Highlights

Entered into a collaboration and license agreement with Bristol Myers Squibb in January 2022 to develop and commercialize up to four iPSC-derived, engineered natural killer cell (iNK) and / or T cell (iT) programs for hematologic malignancies and solid tumors. Under the terms of the agreement, Century received a $100 million upfront payment and Bristol Myers Squibb made a $50 million equity investment in Century Therapeutics common stock. The agreement provides for future program initiation fees and development, regulatory, and commercial milestone payments totaling more than $3 billion plus royalties on product sales.Announced that, subject to U.S. Food and Drug Administration (FDA) acceptance of its Investigational New Drug (IND) application, the Company plans to initiate a Phase 1 trial, ELiPSE-1, to assess CNTY-101 in patients with relapsed/refractory aggressive lymphoma or indolent lymphoma after at least two prior lines of therapy, including patients who have received prior CAR T cell therapy. In vivo data

demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101.Announced plans to focus its initial T cell development program on cells. Data

suggest that CAR-iT cells provide an opportunity to deliver allogeneic T cell therapies without risk for graft-versus-host disease. CNTY-102 will be a CAR- iT candidate targeting CD19, and a second antigen for relapsed/refractory B cell lymphoma and other B cell malignancies. Added to the NASDAQ Biotechnology Index (NASDAQ: NBI) in December 2021.

Upcoming Milestones

Current Good Manufacturing Practice (cGMP) manufacturing facility expected to be operational in 2022.CNTY-101 IND filing remains on track for mid-2022. Subject to U.S. FDA acceptance of its IND application, the Company plans to initiate the Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma in 2022.Expect to submit an IND for CNTY-103 in 2023. CNTY-103 is Centurys first solid tumor candidate for glioblastoma.

Fourth Quarter and Year-end 2021 Financial Results

Cash Position:Cash, cash equivalents, and marketable securities were $358.8 million as of December 31, 2021, as compared to $76.8 million as of December 31, 2020. Net cash used in operations was $89.0 million for the twelve months ended December 31, 2021, compared to $41.3 million for the twelve months ended December 31, 2020.Research and Development (R&D) expenses: R&D expenses were $75.6 million for the year ended December 31, 2021, compared to $39.7 million for the year ended December 31, 2020. The increase in R&D expenses was primarily due to an increase in personnel expenses related to increased headcount to expand the Companys R&D capabilities, costs for preclinical studies, costs for laboratory supplies, and facility costs.General and Administrative (G&A) expenses: G&A expenses were $19.2 million for the year ended December 31, 2021, compared to $9.5 million for the year ended December 31, 2020. The increase was primarily due to an increase in personnel related expense due to an increase in employee headcount and an increase in the Companys professional fees as a result of expanded operations to support its infrastructure as well as additional costs to operate as a public company.Net loss: Net loss was $95.8 million for the year ended December 31, 2021, compared to $53.6 million for the year ended December 31, 2020.

Financial Guidance

The Company expects full year GAAP Operating Expenses to be between $155 million and $165 million including non-cash stock-based compensation expense of $10 million to $15 million. The Company expects its cash, cash equivalents, and marketable securities, including proceeds from the Bristol Myers Squibb collaboration agreement, will support operations into 2025.

About Century Therapeutics

Century Therapeutics, Inc. (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies.We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit https://www.centurytx.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our cash and financial resources, our clinical development plans, the development of our U.S. manufacturing facility, and our financial guidance are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as may, might, will, should, expect, plan, aim, seek, anticipate, could, intend, target, project, contemplate, believe, estimate, predict, forecast, potential or continue or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic on our business and operations; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the Risk Factors section of our most recent filings with the Securities and Exchange Commission and available at http://www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For More Information:

Company: Elizabeth Krutoholow investor.relations@centurytx.com

Investors: Melissa Forst/Maghan Meyers century@argotpartners.com

Media: Joshua R. Mansbach century@argotpartners.com

More:
Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides ... - The Bakersfield Californian

About the opportunity

The Centre for Advanced Food Engineering (CAF) at the University of Sydney is looking for a researcher to drive an industry sponsored research in the field of cellular agriculture. We are looking for an outstanding, motivated and independent synthetic biologist to develop a novel bio-technological platform for the production of protein and cellularized edible scaffolds. The researcher will join a multidisciplinary research team and be mentored by national and international researchers with expertise in the fields of bio-engineering, genetic engineering and tissue engineering. This is an opportunity to develop many aspects of their academic career, engage with industry partners in the field of bioengineering and strengthen national and international collaborations in the emerging field of cellular agriculture.

About you

The University values courage and creativity; openness and engagement; inclusion and diversity; and respect and integrity. As such, we see the importance of recruiting talent aligned to these values and are looking for a Research Associate who has:

We are ideally looking for a candidate with experience with LC-MS, particularly lipidomics as well as experience with elemental analysis and macronutrients profiling.

To apply for this role, please address the following points in a cover letter that you attach to your application:

To keep our community safe, please be aware of our COVID safety precautions which form our conditions of entry for all staff, students and visitors coming to campus.

Sponsorship / work rights for Australia

Please note: Visa sponsorship is not available for this position.

Pre-employment checks

Your employment is conditional upon the completion of all role required pre-employment or background checks in terms satisfactory to the University. Similarly, your ongoing employment is conditional upon the satisfactory maintenance of all relevant clearances and background check requirements. If you do not meet these conditions, the University may take any necessary step, including the termination of your employment.

EEO statement

At the University of Sydney, our shared values include diversity and inclusion and we strive to be a place where everyone can thrive. We are committed to creating a University community which reflects the wider community that we serve. We deliver on this commitment through our people and culture programs, as well as key strategies to increase participation and support the careers of Aboriginal and Torres Strait Islander People, women, people living with a disability, people from culturally and linguistically diverse backgrounds, and those who identify as LGBTIQ. We welcome applications from candidates from all backgrounds.

How to apply

Applications (including a cover letter, CV, and any additional supporting documentation) can be submitted via the Apply button at the top of the page.

If you are a current employee of the University or a contingent worker with access to Workday, please login into your Workday account and navigate to the Career icon on your Dashboard. Click on USYD Find Jobs and apply.

For a confidential discussion about the role, or if you require reasonable adjustment or support filling out this application, please contact Linden Joseph or Rebecca Astar, Recruitment Operations, at recruitment.sea@sydney.edu.au. For specific enquiries about the position please contact Peter Valtchev peter.valtchev@sydney.edu.au.

The University of Sydney

The University reserves the right not to proceed with any appointment.

Applications Close

Sunday 10 April 2022 11:59 PM

Original post:
Research Associate in Synthetic Biology job with UNIVERSITY OF SYDNEY | 286245 - Times Higher Education

Even at the best of times, farming can be a tough business.

Yet as the world grapples with the impacts of Russias invasion of Ukraine, it has actually become pretty frightening times for farmers, says Hertfordshire-based farmer Stephen Roberts.

Food security has been an unfashionable topic for a long time, he adds. But now, we really cannot allow anyone to take their eye off the importance of an island nation being able to feed itself and we need to be looking at any technology that can make us more resource-efficient in farming.

Robotics, says Roberts, is one such technology, or it could be genetic engineering and genetic modification.

British farmers are searching for options to stave off the likelihood of a food crisis which has been exemplified by the Russian presidents invasion of the breadbasket of Europe, such as technology-led solutions including genetic modification (GM).

The latter is an area experts are increasingly pointing to, as the full out over Russias attack on Ukraine filters through. Already the industry was under pressure from labour shortages, after Covid led to hosts of fruit-pickers and butchers leaving Britain.

Roberts farm, which grows cereals and keeps cattle and lamb, has so far avoided the worst of the pain from Putins war - farming organically to reduce reliance on fertilisers such as ammonium nitrate. Yet his peers are struggling.

There's ammonium nitrate nearly tripling in price. Farmers are being quoted prices for diesel which have doubled within the space of 10 days, according to Roberts, with some already pulling back on planting crops such as potatoes to keep costs down.

Read the original:
War forces farmers to think again about GM crops - The Telegraph